Why tapering psychiatric medication
is often harder than expected

The gap between expectation and experience

Most people who start reducing a psychiatric medication are told — by a leaflet, a GP, or a pharmacist — that they should reduce gradually over a few weeks and that any side effects will be mild and short-lived. For some people, especially those who have been on medication for a short time at a low dose, this is broadly accurate.

For many others, it is not. They reduce as instructed and find themselves experiencing significant physical symptoms, intense emotional distress, or both. When they report this, they are sometimes told it is their condition returning — which can lead to medication being reinstated before the nervous system has had time to find its own equilibrium.

This cycle — attempt, distress, reinstatement, repeat — is one of the most common and most avoidable patterns in psychiatric medication management. Understanding why it happens is the first step to doing it differently.

Reason one — the nervous system has adapted to the medication

Psychiatric medications — particularly SSRIs, SNRIs, antipsychotics, benzodiazepines and gabapentinoids — create long-term neurophysiological changes. The brain adapts to the presence of the medication over months and years, altering receptor sensitivity, neurotransmitter activity and regulatory systems to compensate for the drug's effects.

This adaptation is not pathological — it is a normal biological response. But it means that when the medication is reduced, the nervous system is suddenly operating in conditions it has not experienced for years, and needs time to recalibrate. The greater the adaptation — determined primarily by how long the medication has been taken and at what dose — the more time and care the nervous system needs to adjust.

This is why the same approach that works for someone who has been on a medication for three months can fail completely for someone who has been on the same medication for ten years. Duration of use matters enormously, and standard guidance rarely accounts for it adequately.

Reason two — the dose-response relationship is not linear

This is perhaps the most important and most consistently overlooked pharmacological fact in the tapering of psychiatric medications.

Most people — and many clinicians — assume that halving the dose halves the drug's effect on the brain. This is not correct. The relationship between dose and neurological effect follows a curved, hyperbolic function. At higher doses, receptor occupancy is already near-saturated, so reducing the dose by a large amount produces a relatively small change in receptor activity. At lower doses, every milligram removed produces a proportionally much larger neurological effect.

The practical consequence is significant. A reduction from 20mg to 10mg of sertraline produces a far smaller change in serotonin transporter occupancy than a reduction from 5mg to 2.5mg — even though both are a 50% reduction in dose. Equal-step reductions get dramatically harder as the dose gets lower, which is why so many people "sail through" the first few reductions and then hit a wall.

Standard tapering schedules — cutting in half, then in half again — follow a linear logic that simply does not match the pharmacology. This is why they frequently fail, and why hyperbolic tapering — reducing by a percentage of the current dose rather than a fixed amount — is now the approach recommended by NICE.

Reason three — the timescales in standard guidance are too short

Most patient-facing guidance on stopping antidepressants refers to a taper of between two and four weeks. This guidance was written when the evidence on long-term use and withdrawal was limited, and it has not kept pace with clinical experience or more recent research.

For someone who has been on a psychiatric medication for years, a two-to-four-week taper is almost always inadequate. The nervous system needs time — measured in months, not weeks — to adjust at each stage of a gradual reduction. Rushing this process produces withdrawal symptoms that are then misread as clinical deterioration, which leads to reinstatement and a return to square one.

In clinical practice, tapers for people on long-term psychiatric medication routinely take twelve to twenty-four months or longer when done carefully. This is not a failure of the process — it is the process working correctly, at a pace the nervous system can actually manage.

Reason four — appropriate formulations are rarely planned for

Standard psychiatric medications come in a limited range of tablet strengths. Sertraline, for example, is typically available as 50mg and 100mg tablets. Once a taper reaches doses lower than the smallest available tablet, it becomes impossible to continue reducing accurately using standard preparations.

Yet this is exactly the point at which precision matters most — because the neurological impact of each milligram is greatest at low doses. Continuing to cut tablets or skip doses at this stage introduces unpredictability that the nervous system cannot easily tolerate.

Liquid preparations allow precise dosing to fractions of a milligram, making the final stages of a taper genuinely manageable. They are available on prescription for most common psychiatric medications, but they are rarely mentioned in standard guidance and are frequently not planned for until a crisis point is reached. A well-designed taper plans formulation requirements from the outset — not as an afterthought.

Reason five — withdrawal symptoms are routinely misidentified

When a person reducing their medication begins to feel anxious, low, or emotionally unstable, the instinctive clinical response is often to interpret this as the return of the original condition. This interpretation leads to medication being reinstated — sometimes within days of a reduction — before the nervous system has had any chance to settle.

In many cases, what is being experienced is withdrawal. The distinguishing features — physical symptoms, onset closely linked in time to the dose change, new or unfamiliar quality — point clearly to withdrawal rather than relapse. But when these features are not understood or looked for, the distinction is not made, and the person is left believing they are permanently dependent on their medication.

This matters because repeated cycles of reduction and reinstatement are genuinely destabilising, and each cycle reinforces the belief that the medication is necessary when in many cases it is the method of reduction — not the medication's pharmacological necessity — that has prevented success.

Reason six — the absence of a clinical relationship changes everything

Perhaps the most underappreciated factor in why tapering is hard is simply the absence of an ongoing clinical relationship that can interpret what is happening as it happens.

When withdrawal symptoms arise and there is no clinician available to explain them, distinguish them from relapse, and advise on the appropriate response, fear drives the decision-making. Fear typically produces one of two outcomes: either the person pushes through symptoms in a way that is genuinely harmful, or they reinstate the medication unnecessarily. Neither is good clinical management.

A containing clinical relationship — one in which the person can contact someone who understands the process, knows their history, and can make a considered judgement in the moment — is not a luxury in deprescribing. It is a clinical necessity, particularly for people who have been on medication for a long time or who have previously had difficult experiences with reduction.